cAMP Hunter™ eXpress Inducible Human GLP1R Gs Assay (CHO-K1)

Following ligand binding, GPCR activation triggers downstream second messenger signaling that can lead to a cellular response. This assay specifically measures activation of Gs-coupled GPCRs, which stimulate adenylyl cyclase and increase intracellular cAMP levels.

GLP-1R expression is controlled by doxycycline concentration: cells treated with increasing amounts of doxycycline display progressively higher receptor surface density (Figure 1). Once the desired expression level is established, cells are stimulated with a ligand and intracellular cAMP is quantified using the HitHunter™ cAMP detection kit included in the eXpress kit (Figure 2). It is a homogeneous, no-wash competitive immunoassay based on Enzyme Fragment Complementation (EFC) technology. In this format, the luminescent signal is directly proportional to cAMP concentration and therefore reflects the extent of GLP-1R activation


Figure 1. Doxycycline-dependent control of GPCR expression in cAMP Hunter^™ eXpress Inducible GLP-1R GPCR Gαs cells. (A.) Schematic of the doxycycline-inducible expression system. Increasing doxycycline activates the inducible promoter and drives higher GPCR expression at the cell surface.(B.) qRT-PCR analysis of GLP-1R mRNA in cAMP Hunter eXpress Inducible GLP-1R Gαs cells treated with increasing doxycycline concentrations. Relative GLP-1R mRNA, normalized to POLR2, increases dose-dependently, confirming titratable control of receptor expression.


Figure 2. cAMP HitHunter^™ Assay Principle

The kits contain all the reagents needed to detect cAMP in whole cells expressing doxycycline-inducible Gs-coupled receptors following activation by a biologic or small-molecule ligand. After thawing and plating the cells at the desired doxycycline concentration(s), the cells are stimulated with an agonist, leading to cAMP accumulation. The HitHunter cAMP detection reagents (included in the kit) are then used to measure this accumulation using a simple homogeneous protocol described in this manual (Figure 3). The assay is compatible with agonist-mode testing in both 96-well and 384-well plate formats.


Figure 3. cAMP Hunter eXpress Inducible GLP-1R Assay Workflow – Agonist

The following three dose-response curves (Figure 4) compare the pharmacological behavior of exendin-4 (A.), tirzepatide (B.), and orforglipron (C.) in the cAMP Hunter eXpress Inducible Human GLP-1R assay across increasing levels of doxycycline-induced receptor expression. By precisely controlling GLP-1R density, the system enables direct assessment of how receptor abundance influences both potency and efficacy.


Figure 4. Functional Characterization of Exendin-4 (A.), Tirzepatide (B.), and Orforglipron (C.) using the cAMP Hunter eXpress Inducible GLP-1R Assay.

Overall, the data show that the inducible GLP-1R assay generates robust, reproducible, receptor density-dependent cAMP responses. Importantly, it allows clear discrimination between full and partial agonists, as illustrated by the distinct pharmacological profiles of the three compounds tested. This includes a peptide agonist (exendin-4), a dual incretin peptide (tirzepatide), and a small molecule agonist (orforglipron), demonstrating that the assay is well suited to profile diverse ligand classes under defined receptor expression conditions.

These findings highlight the value of the assay as a sensitive and flexible platform for GLP-1R characterization in obesity drug discovery. The controlled inducible system makes it possible to investigate complex pharmacology, compare compounds across receptor densities, and distinguish differences in agonist behavior with confidence.

Figure 5 illustrates the performance of the cAMP Hunter eXpress Inducible GLP-1R assay across two complementary readouts. Three independent cell lots were analyzed by FACS to assess doxycycline-dependent GLP-1R expression, showing a consistent increase in receptor number per cell with rising doxycycline concentrations and strong reproducibility across duplicate runs (Figure 5A) . Exendin-4 dose-response curves generated under the same conditions were used to plot EC₅₀ values against receptor number per cell, revealing a clear relationship between GLP-1R expression level and functional potency (Figure 5B).

Together, these data demonstrate robust lot-to-lot and run-to-run consistency, as well as the ability of the inducible assay to capture receptor density-dependent pharmacology.


Figure 5. Lot-to-Lot Reproducibility and GLP-1R Expression-Dependent Exendin-4 Potency in the Inducible Assay. (A.) Doxycycline-dependent GLP-1R expression was assessed by FACS across three independent cell lots, showing strong lot-to-lot and run-to-run consistency. (B.) Exendin-4 potency was then evaluated across the same conditions, revealing a clear relationship between receptor expression level and EC₅₀.